The burgeoning landscape of therapeutic interventions for obesity disorders has witnessed considerable attention focused on GLP-3 agonists and, more recently, the dual GIP and GLP-3 agonist retatrutide. While both https://mayaqlop559617.blogripley.com/39832193/glp-3-retatrutide-a-comparative-analysis